• Vaccine Name: SARS-CoV N + SARS-CoV M DNA vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: DNA vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: N, membrane protein (M) (Shi et al., 2006)
• nucleocapsid protein (N) gene of SARS-CoV gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• membrane protein (M) gene of SARS-CoV gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: DNA vaccine made from recombinant plasmids containing membrane protein (M) and nucleocapsid protein (N) sequences constructed then expressed and purified from E. coli bacteria (Shi et al., 2006)

Vole Response

• Vaccination Protocol: 100 μg injected (Shi et al., 2006)
• Immune Response: increased N-specific antibodies compared to Vaccine 5732, increased lymphocyte proliferation specific to N antigen than Vaccine 5732 (Shi et al., 2006)
• Challenge Protocol: 100 μg injected (Shi et al., 2006)
• Efficacy: 6/7 voles protected (Shi et al., 2006)

Mouse Response

• Host Strain: Balb/c (Shi et al., 2006)
• Vaccination Protocol: 20 μg of intramuscular vaccine injection (Shi et al., 2006)
• Immune Response: Production of N-specific IgG antibodies (paricularly IgG2a), Lymphocyte proliferation, Production of IFN-γ, IL-2, IL-4, Increased CD4+ and CD8+ levels (Shi et al., 2006)